NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

Background: Selinexor (SEL) is an oral inhibitor of nuclear export protein Exportin 1 (XPO1) previously shown to upregulate programmed cell death protein 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression. Objective: To investigate the safety and antitumor activity of SEL,...

Full description

Saved in:
Bibliographic Details
Main Authors: Joan R. Choo, Santhiay Nathan Jeraj, Raghav Sundar, Wei Peng Yong, Matilda Lee, Yiqing Huang, Yugarajah Asokumaran, Gloria H. J. Chan, Natalie Y. L. Ngoi, Andrea L. A. Wong, Ross A. Soo, Cheng Ean Chee, Joline S. J. Lim, Boon Cher Goh, Soo Chin Lee, David S. P. Tan
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251339930
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17588359251339930

Similar Items